EXHIBIT: This study is assessing how safe and feasible an exercise program alongside immunotherapy treatment is for people diagnosed with melanomaThe safety and feasibility of exercise in patients with melanoma undergoing adjuvant immunotherapy with immune checkpoint inhibitor therapy – the EXHIBIT Study

Trial purpose

Cancer treatment; Side effect and wellbeing

Tumor type

Skin

Age

18+

Trial acronym

EXHIBIT

Summary

You may be eligible for this study if you are aged 18 years or over, have a diagnosis of cutaneous melanoma and are scheduled to receive adjuvant immune checkpoint inhibitor (ICI) immunotherapy treatment.

Eligible participants will be randomly allocated to either an exercise intervention or standard medical care.

Participants randomised to the exercise group will receive a structured exercise intervention for the duration of their ICI immunotherapy treatment (approximately 12 months). The intervention will involve 3 exercise sessions per week (45-60minutes per session) involving both supervised and unsupervised exercise sessions.

Participants randomised to the control group will receive usual medical care and general exercise advice as per the current exercise oncology guidelines. 

All participants will be asked to complete a variety of questionnaires, undergo fitness testing, and provide blood samples. 

It is hoped that findings from this study will inform researchers of the effect of exercise concurrent to ICI immunotherapy, following surgery, for patients with melanoma. 

Conditions

This trial is treating people with cutaneous melanoma who have had surgery and are scheduled to receive adjuvant immune checkpoint inhibitor immunotherapy treatment